NCT00700336 · STUDY IN CONTEXT

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-malignant-mesothelioma
nct id: NCT00700336
trial label: Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 3
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
outcome key
om-0000
source section id
NCT00700336-om-0000
source outcome index
0
endpoint
4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin
endpoint definition
Planned: Forty-two patients were to be treated in Arm A. If ≥ 23 patients (\>54%) were free of progression and death at 4 months, then the study regimen would be considered for further evaluation in this indication.
time origin
End of study
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
outcome key
om-0000
arm key
OG000
arm label
Pemetrexed, Cisplatin, and CBP501
regimen
Pemetrexed, Cisplatin, and CBP501 administered once every 3 weeks
analyzed count
40
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700336-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
outcome key
om-0000
arm key
OG001
arm label
Pemetrexed and Cisplatin
regimen
Pemetrexed and Cisplatin every three weeks
analyzed count
23
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00700336-om-0000#groups/OG001

harms

release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
harm key
EG000
source section id
NCT00700336-ae
event group key
EG000
event group label
Pemetrexed, Cisplatin, and CBP501: Phase 2
serious affected
21
serious at risk
40
other affected
28
other at risk
40
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
harm key
EG001
source section id
NCT00700336-ae
event group key
EG001
event group label
Pemetrexed and Cisplatin: Phase 2
serious affected
13
serious at risk
23
other affected
15
other at risk
23
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-malignant-mesothelioma
nct id
NCT00700336
harm key
EG002
source section id
NCT00700336-ae
event group key
EG002
event group label
Pemetrexed, Cisplatin, and CBP501: Phase 1
serious affected
5
serious at risk
6
other affected
6
other at risk
6
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice